Antiviral therapy could reduce the risk of hepatocellular carcinoma (HCC) among persons with chronic hepatitis B virus (HBV) infection.
Dr Stuart Gordon and colleagues evaluated the relationship between therapy for chronic HBV infection, and HCC incidence using data from a longitudinal study of patients at 4 US healthcare centers.
The research team analyzed electronic health records of 2671 adult participants in the Chronic Hepatitis Cohort Study who were diagnosed with chronic HBV infection from 1992 through 2011.
Data analyzed were collected for a median of 5 years.
Propensity-score adjustment was used to reduce bias, and Cox regression was used to estimate the relationship between antiviral treatment and HCC.
The primary outcome was time to event of HCC incidence.
|3% developed HCC during follow-up period|
|Clinical Gastroenterology & Hepatology|
Of study subjects, the team found that 3% developed HCC during follow-up period.
Of these, 20 cases were among the 820 patients with a history of antiviral HBV therapy, and 47 cases among the 1851 untreated patients.
The researchers found that patients who received antiviral therapy had a lower risk of HCC than those who did not receive antiviral therapy, after adjusting for abnormal level of alanine aminotransferase.
In a subgroup analysis, the team noted that antiviral treatment was associated with a lower risk of HCC after adjusting for serum markers of cirrhosis.
In a separate subgroup analysis of patients with available data on HBV DNA viral load, treated patients with viral loads >20,000 IU/mL had a significantly lower risk of HCC than untreated patients with viral loads >20,000 IU/mL.
Dr Gordon's team commented, "In a large geographically, clinically, and racially diverse US cohort, antiviral therapy for chronic HBV infection was associated with a reduced risk for HCC."